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Decisions about choice of outcome measures outside of the economics context tend to focus 
on a two-way conflict between (i) the ideal form of measurement in any specific context and 
(ii) what is practically feasible.  But for measurement for economic purposes, there are two 
additional, related, conflicts: (iii) what is required of the measure for it to be consistent with 
economic theory/the economic decision-making context, and (iv) what value judgements 
are acceptable within this theoretical approach.    
The purpose of outcome measurement for economics is its use in economic evaluation to 
enable decision-makers to weigh up costs and benefits of alternative courses of action: 
relatively simple decisions such as whether to spend on medication or cognitive approaches 
to relieve pain for palliative care patients; or more complex decisions such as whether to 
spend more on pain relief for palliative care patients, or more on constipation management 
for this same group of patients, or more on providing cochlear implants for those with 
hearing loss, or more on providing social care for those with learning disability.  Economists 
talk in terms of technical efficiency (achieving a specific outcome at least cost) or allocative 
efficiency (achieving a pattern of spending that provides those services most valued by 
society).  Outcome measurement for technical efficiency questions is relatively simple: it 
often mirrors the outcome measurement required for randomised controlled trials and, in 
the first example above, could focus on pain.  Combined with cost information,analysis  can 
then determine the most efficient alternative.  As soon as decisions move in the direction of 
allocative efficiency, however, everything becomes much more complex; it is at this point 
that the Quality-Adjusted Life-Year, or QALY, enters the equation. 
The QALY is a means of trying to combine quality and length of life into a single outcome 
that can be used in all conditions, thus enabling comparability across all interventions on the 
fundamental issue that is perceived as important to health decision-makers: gains in health 
(1, 2). Value judgements explicitly or implicitly include that:  
 generic health functioning (what a person actually does/is in terms of their health 
only) is the appropriate evaluative space (rather than, for example, broader notions 
such as capability wellbeing (what a person is able to achieve in life more broadly));  
 the person is the best judge of their own health state; 
 the population is the best judge of the value of that health state;  
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  ‘perfect health’ has a value of one, the state of ‘being dead’ a value of zero, and that 
values in-between (and indeed below zero), can be used to represent various health 
states according to population preferences; 
 the values of intermediate states are judged by the ‘average’ individual’s willingness 
to trade-off quality of life in that state against time in that state or by alternative 
methods such as the ‘average’ individual’s willingness to trade between a certain 
health state and the risk of dying;  
 time in a state can be multiplied by the value for the quality of life in that state; 
 the purpose of the health system is to maximise health gain across the population. 
Generic health measures with associated population value sets (or ‘tariffs’) are commonly 
preferred to condition-specific measures, as they provide comparabilty across interventions.  
A key measure recommended by decision-makers in a number of countries is the EuroQol 
EQ-5D, which comprises a quality of life measure with five dimensions: Mobility; Self-care; 
Usual activities; Pain/discomfort; and Anxiety/depression.  There are two versions; ‘EQ-5D’ is 
used here as a shorthand to include both three level (EQ-5D-3L) (3) and five level (EQ-5D-
5L) (4, 5) versions. 
Although some support using a QALY approach to evaluate palliative and end of life 
interventions (6), there is also concern in this context about the appropriateness of basing 
decisions upon economic evaluations using QALYs (7-9), with a recent integrative review 
identifying three challenges (10). Conceptually, these focused on two of the value 
judgements outlined above: concerns about the adequacy of the evaluative space, and 
concerns about the additivity of time.  A third challenge related to a more practical 
implication of using QALYs, in that the low levels of remaining life expectancy inevitably 
restrict potential QALY gains (10) (potentially perceived as unfair).  There was little 
discussion of appropriate methods for generating tariffs or of appropriate populations from 
whom to generate these tariffs, perhaps reflecting that the few attempts to go ‘beyond’ the 
generic health QALY in this context have so far focused primarily on the nature of the 
evaluative space, rather than its valuation.   
Nevertheless, moving beyond generic health measures such as EQ-5D to form QALYs, is an 
active area of investigation in evaluation of palliative and end of life care, with research 
moving in two directions, employing differing value judgements.  The first remains within 
the general QALY paradigm whilst relaxing the value judgement around use of generic 
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health measures, in favour of using a ‘health’ measure that reflects health issues faced by 
those receiving palliative care (11).  The second is more radical, questioning more of the 
value judgements associated with QALY maximisation (9) and shifting focus towards 
capability wellbeing amongst those at end of life (12-14) and persons close to them (15).  
These approaches mirror those outside of the palliative/end of life context. 
The first tranche of research builds on an existing, widely used measure, the Palliative care 
Outcomes Scale (POS) and its forerunner, the Support Team Assessment Schedule(16), to 
develop a new scale, the POS-E.  POS-E has been derived from the existing ten-item, five 
level POS (11).  This is a point at which practical considerations enter: the POS scale itself is 
too large to feasibly produce a full value set, and so a derived seven-item scale has been 
generated, with each item having smaller numbers (two or three) of levels (11).  Dimensions 
of POS-E are: Pain; Other symptoms; Depression; Anxiety; Family anxiety; Feeling good; and 
Practical matters.   
There are further challenges for the POS-E before it can be fully used in economic 
evaluation.  As yet, there are no published values, and the validity of the shortened version 
needs testing.  Assuming that valuation methods conform to the usual assumption of 
valuing death at zero, using POS-E for decision making within palliative care (technical 
efficiency) may be relatively uncontroversial.  Even if it were used just in this context, 
however, the question of whether existing cost-effectiveness thresholds are appropriate 
would need to be addressed.  For use in allocative decisions, it is likely that mapping to 
existing generic measures would be required. 
The second tranche of work builds on a broader research programme (ICECAP) to design 
capability wellbeing measures for use in economic evaluation across the life-course.  The 
seven items within the ICECAP Supportive Care Measure (ICECAP-SCM) were generated 
through in-depth interviews with individuals at different points along the trajectory towards 
death.  They comprise: Choice; Love and affection; freedom from Physical suffering; freedom from 
Emotional suffering; Dignity; Support; and Preparation (12).  Both pilot (17) and full (14) 
valuation exercises with members of the public, using a technique known as best-worst 
scaling (14,17,18), have recently been published; values are generated between full capability 
and no capability, and death is assumed to be a state of no capability (18).  The measure is 
feasible for use with hospice patients (13) and a companion close person measure (ICECAP-
CPM) has been published (15).  More generally, research has considered alternative 
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approaches to decision-making, assuming that the focus of decision making is on those not 
yet achieving a ‘sufficient’ level of capability (19). 
As with POS-E, there are challenges still to be addressed in using ICECAP-SCM in decision 
making and, given the scale of ambition in moving into a broader capabilty wellbeing 
paradigm, these are probably greater.  For ICECAP-SCM there are, as yet, no large validity 
studies of the use of the measure although the measure is incorporated into a number of 
ongoing studies.  Values are generated from the general population, but values from those at 
end of life might be more appropriate.  More generally, there are issues around what an 
appropriate monetary threshold would be for capability measures (the focus of a current 
research study using deliberative methods (20)) and how to shift between measures as a 
person moves through the life-course.   
To conclude, we return to the dual themes of conflict and compromise introduced in the 
opening paragraph.  A shift in focus within the economic paradigm is not as simple as 
choosing one measure over another; it also requires engagement with relevant economic 
theory, the extensive value judgements incorporated into any approach, and the subsequent 
decision making process.  Using EQ-5D within the QALY paradigm incorporates a value 
judgement about what is important to patients at end of life that many professionals 
working within palliative care find unacceptable.  Alternatives are on the horizon, but these 
require further work and exploration, although including either one or other of these 
measures alongside EQ-5D in as many studies as possible will add to existing evidence, and 
‘future-proof’ studies as these alternatives become more extensively used.  Just as important, 
there is an urgent need for new research within health economics to address other 
fundamental aspects of valuation, particularly in relation to the issues around the additivity 
of time discussed by Normand (8) and highlighted by Wichmann et al (10).  Such research 
can also be expected to introduce further conflict and generate new compromises.   
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